SCHEMBL5828700

SCHEMBL5828700

COc1ccc(CN(C)NCC(O)c2ccc(O)c(O)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 4/20 0.50
SLC6A4 P31645 2/20 0.50
HTR1A P08908 1/20 0.50
SLC6A2 P23975 1/20 0.50
ADRB2 P07550 10/20 0.49
ADRB3 P13945 7/20 0.49
ADRB1 P08588 7/20 0.49
MAPT P10636 5/20 0.49
TDP1 Q9NUW8 4/20 0.49
KDM4E B2RXH2 4/20 0.49
DRD2 P14416 4/20 0.49
TSHR P16473 4/20 0.49
MAPK1 P28482 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MTOR P42345 3/20 0.49
CYP1A2 P05177 3/20 0.49
CYP3A4 P08684 3/20 0.49
DRD3 P35462 3/20 0.49
HSD17B10 Q99714 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9768301 0.77 MAPT (0.68) ADRA1AADRB2ADRB3ADRB1MAPT
SCHEMBL11810215 0.77 ADRB2 (0.73) ADRA1ASLC6A4HTR1ASLC6A2ADRB2
SCHEMBL5828703 0.73 AOC3 (0.50) ADRA1ASLC6A4HTR1ASLC6A2ADRB2
Oxalic Acid SCHEMBL9239982 0.71 KDM4E (0.64) ADRA1ASLC6A4HTR1ASLC6A2ADRB2
Oxalic Acid SCHEMBL7318481 0.71 KDM4E (0.64) ADRA1ASLC6A4HTR1ASLC6A2ADRB2
SCHEMBL5828705 0.71 AOC3 (0.50) ADRA1AADRB2ADRB3ADRB1MAPT
SCHEMBL11810223 0.69 ADRB2 (0.59) ADRA1ASLC6A4HTR1ASLC6A2ADRB2
SCHEMBL11317081 0.69 ADRB2 (0.53) ADRA1ASLC6A4HTR1ASLC6A2ADRB2
Racepinephrine SCHEMBL3815 0.67 KDM4E (1.00) ADRA1AHTR1ASLC6A2ADRB2ADRB3
L-Adrenaline SCHEMBL11647 0.67 KDM4E (1.00) ADRA1AHTR1ASLC6A2ADRB2ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109330-B2 Purine inhibitors of cyclin dependent kinase 2 and IκB-α CV THERAPEUTICS, INC. (US) 2006-09-19 US disclosed
US-20050080261-A1 Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha LUM ROBERT T (US) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080261-A1 Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha IKBKB, NFKB1, CDK4 ADRA1A 1991/4885SLC6A4 2527/4885HTR1A 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.